This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.

This book contains 28 chapters representing the opinion of key vascular specialists. It covers a wide spectrum of definition and criteria of critical limb ischemia (CLI), its pathophysiology, epidemiology, assessment, and therapy. Objective criteria, which are associated with the definition of CLI, have been the source of many debates and, therefore, their disadvantages and limitations are presented and alternatives and recommendations are suggested. Present-day medical treatment of CLI includes spinal cord stimulation, antiplatelet drugs, defibrinating agents, vasoactive substances, and prostanoids. Therapies of choice, such as distal bypass surgery for extensive arterial disease, and alternative procedures are also surveyed. Clinical and surgical specialists concerned with endovascular and surgical intervention will benefit from this engaging treatise that stretches from general to specific medical conditions of CLI, quality of life, long-term morbidity and mortality, and the role of primary amputation.